However, since there is a conflicting debate on the function of VEGFR-1 in eye diseases, those side effects may also be attributable to the antibody’s mechanism of action (MOA) based on capturing VEGF, resulting in inhibition of VEGF receptor-1 (VEGFR-1) signaling [15,16,17,18]. The gene discussed is FLT1; the disease is eye disorder.